Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NMBR | P28336 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6264591 | 0.87 | BCHE (0.56) | MAPTTP53LMNATHRBMMP2 | |
| SCHEMBL7201043 | 0.84 | KDM4E (0.61) | MAPTLMNAMMP2KDM4EAPAF1 | |
| SCHEMBL9594574 | 0.84 | MMP2 (0.63) | MAPTTP53LMNATHRBMMP2 | |
| SCHEMBL12992803 | 0.84 | MAPT (0.62) | MAPTTP53LMNATHRBMMP2 | |
| SCHEMBL13940115 | 0.84 | MAPT (0.62) | MAPTTP53LMNATHRBMMP2 | |
| SCHEMBL28174733 | 0.84 | KCNT1 (0.64) | MAPTTP53LMNATHRBMMP2 | |
| Hydrochloric Acid SCHEMBL5385683 | 0.83 | MMP2 (0.62) | MAPTTP53LMNATHRBMMP2 | |
| Hydrochloric Acid SCHEMBL5385686 | 0.83 | MMP2 (0.62) | MAPTTP53LMNATHRBMMP2 | |
| SCHEMBL24590211 | 0.82 | MMP2 (0.61) | MAPTTP53LMNATHRBMMP2 | |
| SCHEMBL3185689 | 0.82 | TACR1 (0.74) | MAPTTP53LMNATHRBMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046246-A1 | METHODS FOR TREATING OSTEOCLAST-RELATED DISEASE, COMPOUNDS AND COMPOSITIONS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010071826-A2 | METHODS FOR TREATING OSTEOCLAST-RELATED DISEASE, COMPOUNDS AND COMPOSITIONS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046246-A1 | METHODS FOR TREATING OSTEOCLAST-RELATED DISEASE, COMPOUNDS AND COMPOSITIONS THEREOF | CTSB, SOST, CTSG | MAPT 3657/4885TP53 3867/4885LMNA 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.